Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of FT522 in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Lymphoma

NCT05950334 is registered in ClinicalTrials.gov with Fate Therapeutics as lead sponsor.

NCT NCT05950334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05950334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of FT522 in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Lymphoma
Lead sponsor
Fate Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
November 16, 2023
Completion date
June 30, 2025
Enrollment
20 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory b-cell lymphoma